Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in a man's blood. For this test, a blood sample is sent to a laboratory for analysis.
麻豆原创 Analysis and Insights: Global Prostate Specific Antigen (PSA) Biomarker 麻豆原创
The global Prostate Specific Antigen (PSA) Biomarker market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Prostate Specific Antigen (PSA) Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Prostate Specific Antigen (PSA) Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Prostate Specific Antigen (PSA) Biomarker is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Prostate Specific Antigen (PSA) Biomarker include Abbott, Siemens Healthcare, DiaSorin, Roche, Tosoh Bioscience, Fujirebio, BodiTech, GE Healthcare and Endocare, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Prostate Specific Antigen (PSA) Biomarker market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Prostate Specific Antigen (PSA) Biomarker, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Prostate Specific Antigen (PSA) Biomarker, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Prostate Specific Antigen (PSA) Biomarker revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Prostate Specific Antigen (PSA) Biomarker market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Prostate Specific Antigen (PSA) Biomarker revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Abbott, Siemens Healthcare, DiaSorin, Roche, Tosoh Bioscience, Fujirebio, BodiTech, GE Healthcare and Endocare, etc.
By Company
Abbott
Siemens Healthcare
DiaSorin
Roche
Tosoh Bioscience
Fujirebio
BodiTech
GE Healthcare
Endocare
Quest Diagnostics
Bio-Rad Laboratories
QIAGEN
Myriad RBM
Segment by Type
Blood
Semen
Urine
Segment by Application
Diagnostics
Drug Discovery
Personalized Medicine
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Prostate Specific Antigen (PSA) Biomarker in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Prostate Specific Antigen (PSA) Biomarker companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Prostate Specific Antigen (PSA) Biomarker revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Blood
1.2.3 Semen
1.2.4 Urine
1.3 麻豆原创 by Application
1.3.1 Global Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Diagnostics
1.3.3 Drug Discovery
1.3.4 Personalized Medicine
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Perspective (2018-2029)
2.2 Global Prostate Specific Antigen (PSA) Biomarker Growth Trends by Region
2.2.1 Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Prostate Specific Antigen (PSA) Biomarker Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Prostate Specific Antigen (PSA) Biomarker Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Dynamics
2.3.1 Prostate Specific Antigen (PSA) Biomarker Industry Trends
2.3.2 Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Drivers
2.3.3 Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Challenges
2.3.4 Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Prostate Specific Antigen (PSA) Biomarker by Players
3.1.1 Global Prostate Specific Antigen (PSA) Biomarker Revenue by Players (2018-2023)
3.1.2 Global Prostate Specific Antigen (PSA) Biomarker Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Prostate Specific Antigen (PSA) Biomarker, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Concentration Ratio
3.4.1 Global Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Prostate Specific Antigen (PSA) Biomarker Revenue in 2022
3.5 Global Key Players of Prostate Specific Antigen (PSA) Biomarker Head office and Area Served
3.6 Global Key Players of Prostate Specific Antigen (PSA) Biomarker, Product and Application
3.7 Global Key Players of Prostate Specific Antigen (PSA) Biomarker, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Prostate Specific Antigen (PSA) Biomarker Breakdown Data by Type
4.1 Global Prostate Specific Antigen (PSA) Biomarker Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Prostate Specific Antigen (PSA) Biomarker Forecasted 麻豆原创 Size by Type (2024-2029)
5 Prostate Specific Antigen (PSA) Biomarker Breakdown Data by Application
5.1 Global Prostate Specific Antigen (PSA) Biomarker Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Prostate Specific Antigen (PSA) Biomarker Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size (2018-2029)
6.2 North America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Type
6.2.1 North America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Type (2018-2023)
6.2.2 North America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Type (2024-2029)
6.2.3 North America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Share by Type (2018-2029)
6.3 North America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Application
6.3.1 North America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Application (2018-2023)
6.3.2 North America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Application (2024-2029)
6.3.3 North America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Share by Application (2018-2029)
6.4 North America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Country
6.4.1 North America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Country (2018-2023)
6.4.3 North America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size (2018-2029)
7.2 Europe Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Type
7.2.1 Europe Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Type (2018-2023)
7.2.2 Europe Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Type (2024-2029)
7.2.3 Europe Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Share by Type (2018-2029)
7.3 Europe Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Application
7.3.1 Europe Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Application (2018-2023)
7.3.2 Europe Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Application (2024-2029)
7.3.3 Europe Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Share by Application (2018-2029)
7.4 Europe Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Country
7.4.1 Europe Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Country (2018-2023)
7.4.3 Europe Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size (2018-2029)
8.2 China Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Type
8.2.1 China Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Type (2018-2023)
8.2.2 China Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Type (2024-2029)
8.2.3 China Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Share by Type (2018-2029)
8.3 China Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Application
8.3.1 China Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Application (2018-2023)
8.3.2 China Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Application (2024-2029)
8.3.3 China Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size (2018-2029)
9.2 Asia Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Type
9.2.1 Asia Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Type (2018-2023)
9.2.2 Asia Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Type (2024-2029)
9.2.3 Asia Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Share by Type (2018-2029)
9.3 Asia Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Application
9.3.1 Asia Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Application (2018-2023)
9.3.2 Asia Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Application (2024-2029)
9.3.3 Asia Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Share by Application (2018-2029)
9.4 Asia Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Region
9.4.1 Asia Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Region (2018-2023)
9.4.3 Asia Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size (2018-2029)
10.2 Middle East, Africa, and Latin America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Prostate Specific Antigen (PSA) Biomarker 麻豆原创 Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Details
11.1.2 Abbott Business Overview
11.1.3 Abbott Prostate Specific Antigen (PSA) Biomarker Introduction
11.1.4 Abbott Revenue in Prostate Specific Antigen (PSA) Biomarker Business (2018-2023)
11.1.5 Abbott Recent Developments
11.2 Siemens Healthcare
11.2.1 Siemens Healthcare Company Details
11.2.2 Siemens Healthcare Business Overview
11.2.3 Siemens Healthcare Prostate Specific Antigen (PSA) Biomarker Introduction
11.2.4 Siemens Healthcare Revenue in Prostate Specific Antigen (PSA) Biomarker Business (2018-2023)
11.2.5 Siemens Healthcare Recent Developments
11.3 DiaSorin
11.3.1 DiaSorin Company Details
11.3.2 DiaSorin Business Overview
11.3.3 DiaSorin Prostate Specific Antigen (PSA) Biomarker Introduction
11.3.4 DiaSorin Revenue in Prostate Specific Antigen (PSA) Biomarker Business (2018-2023)
11.3.5 DiaSorin Recent Developments
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Prostate Specific Antigen (PSA) Biomarker Introduction
11.4.4 Roche Revenue in Prostate Specific Antigen (PSA) Biomarker Business (2018-2023)
11.4.5 Roche Recent Developments
11.5 Tosoh Bioscience
11.5.1 Tosoh Bioscience Company Details
11.5.2 Tosoh Bioscience Business Overview
11.5.3 Tosoh Bioscience Prostate Specific Antigen (PSA) Biomarker Introduction
11.5.4 Tosoh Bioscience Revenue in Prostate Specific Antigen (PSA) Biomarker Business (2018-2023)
11.5.5 Tosoh Bioscience Recent Developments
11.6 Fujirebio
11.6.1 Fujirebio Company Details
11.6.2 Fujirebio Business Overview
11.6.3 Fujirebio Prostate Specific Antigen (PSA) Biomarker Introduction
11.6.4 Fujirebio Revenue in Prostate Specific Antigen (PSA) Biomarker Business (2018-2023)
11.6.5 Fujirebio Recent Developments
11.7 BodiTech
11.7.1 BodiTech Company Details
11.7.2 BodiTech Business Overview
11.7.3 BodiTech Prostate Specific Antigen (PSA) Biomarker Introduction
11.7.4 BodiTech Revenue in Prostate Specific Antigen (PSA) Biomarker Business (2018-2023)
11.7.5 BodiTech Recent Developments
11.8 GE Healthcare
11.8.1 GE Healthcare Company Details
11.8.2 GE Healthcare Business Overview
11.8.3 GE Healthcare Prostate Specific Antigen (PSA) Biomarker Introduction
11.8.4 GE Healthcare Revenue in Prostate Specific Antigen (PSA) Biomarker Business (2018-2023)
11.8.5 GE Healthcare Recent Developments
11.9 Endocare
11.9.1 Endocare Company Details
11.9.2 Endocare Business Overview
11.9.3 Endocare Prostate Specific Antigen (PSA) Biomarker Introduction
11.9.4 Endocare Revenue in Prostate Specific Antigen (PSA) Biomarker Business (2018-2023)
11.9.5 Endocare Recent Developments
11.10 Quest Diagnostics
11.10.1 Quest Diagnostics Company Details
11.10.2 Quest Diagnostics Business Overview
11.10.3 Quest Diagnostics Prostate Specific Antigen (PSA) Biomarker Introduction
11.10.4 Quest Diagnostics Revenue in Prostate Specific Antigen (PSA) Biomarker Business (2018-2023)
11.10.5 Quest Diagnostics Recent Developments
11.11 Bio-Rad Laboratories
11.11.1 Bio-Rad Laboratories Company Details
11.11.2 Bio-Rad Laboratories Business Overview
11.11.3 Bio-Rad Laboratories Prostate Specific Antigen (PSA) Biomarker Introduction
11.11.4 Bio-Rad Laboratories Revenue in Prostate Specific Antigen (PSA) Biomarker Business (2018-2023)
11.11.5 Bio-Rad Laboratories Recent Developments
11.12 QIAGEN
11.12.1 QIAGEN Company Details
11.12.2 QIAGEN Business Overview
11.12.3 QIAGEN Prostate Specific Antigen (PSA) Biomarker Introduction
11.12.4 QIAGEN Revenue in Prostate Specific Antigen (PSA) Biomarker Business (2018-2023)
11.12.5 QIAGEN Recent Developments
11.13 Myriad RBM
11.13.1 Myriad RBM Company Details
11.13.2 Myriad RBM Business Overview
11.13.3 Myriad RBM Prostate Specific Antigen (PSA) Biomarker Introduction
11.13.4 Myriad RBM Revenue in Prostate Specific Antigen (PSA) Biomarker Business (2018-2023)
11.13.5 Myriad RBM Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Abbott
Siemens Healthcare
DiaSorin
Roche
Tosoh Bioscience
Fujirebio
BodiTech
GE Healthcare
Endocare
Quest Diagnostics
Bio-Rad Laboratories
QIAGEN
Myriad RBM
听
听
*If Applicable.
